High expression of <i>YKT6</i> associated with progression and poor prognosis of hepatocellular carcinoma

Xu, Jia-Ze; Jiang, Jun-Jie; Xu, Hao-jie; Sun, Xiaodong; Liu, Zhengchuang; Hu, Zhiming

doi:10.1080/00365521.2021.1961305

Cited by 15 publications

(13 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, increased malignancy eventually leads to a poor prognosis [ 14 ]. For example, the increased expression of YKT6 is correlated with the tumor size, Edmondson Grade, metastasis, and microvascular invasion and predicts a poorer prognosis in patients with HCC [ 15 ]. In this study, a Kaplan–Meier curve revealed that the increase in SRSF9 expression can significantly reduce the overall survival time of patients.…”

Section: Discussionmentioning

confidence: 99%

High expression of serine and arginine-rich splicing factor 9 (SRSF9) is associated with hepatocellular carcinoma progression and a poor prognosis

et al. 2022

View full text Add to dashboard Cite

Background Serine and arginine-rich splicing factor 9 (SRSF9) has been linked to the occurrence and progression of various cancers; however, its effects and mechanism of action hepatocellular carcinoma (HCC) have not been reported. In this study, we used a bioinformatics approach and in vitro assays to evaluate the expression of SRSF9 in HCC, its prognostic value, and its underlying regulatory mechanisms, including analyses of related pathways and the role of methylation. Methods Transcriptomic and DNA methylation data for 357 HCC cases and 50 paratumor tissues in The Cancer Genome Atlas database were obtained. Additionally, protein expression data for cell lines and tissue samples were obtained from the Human Protein Atlas. The CMap databased was used to predict candidate drugs targeting SRSF9. Various cell lines were used for in vitro validation. Results SRSF9 expression was significantly elevated in HCC and was negatively regulated by its methylation site cg06116271. The low expression of SRSF9 and hypermethylation of cg06116271 were both associated with a longer overall survival time. A correlation analysis revealed ten genes that were co-expressed with SRSF9; levels of CDK4, RAN, DENR, RNF34, and ANAPC5 were positively correlated and levels of RBP4, APOC1, MASP2, HP, and HPX were negatively correlated with SRSF9 expression. The knockdown of SRSF9 in vitro inhibited the proliferation and migration of HCC cells and significantly reduced the expression of proteins in the Wnt signaling pathway (DVL2 and β-catenin) and cell cycle pathway (Cyclin D and Cyclin E). A CMap analysis identified two drugs, camptothecin and apigenin, able to target and inhibit the expression of SRSF9. Conclusions This study expands our understanding of the molecular biological functions of SRSF9 and cg06116271 and provides candidate diagnostic and therapeutic targets for HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

High expression of serine and arginine-rich splicing factor 9 (SRSF9) is associated with hepatocellular carcinoma progression and a poor prognosis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Consistent with the nding, our results revealed a relation between high level of YKT6 and poor OS (P = 0.017) and DFS (P = 0.019) in patients with LUAD. XU et al reported that over-expression of YTK6 was correlated with worse prognosis in patients with hepatocellular carcinoma 11 . Similarly, we observed that high level of YKT6 was positive association with poor prognosis OS (P = 0.0013) and DFS (P = 0.019) in LIHC, which is in accordance with XU's report.…”

Section: Discussionmentioning

confidence: 99%

“…Hepatocellular carcinoma (HCC) study has revealed that overexpressed expression of YKT6 was closely associated with prognosis of HCC patients 11 . Recent research about oral squamous cell carcinoma (OSCC) suggested that overexpression of YKT6 was related to cell invasion and metastasis, and low level of YKT6 was associated with CD8 + T cell in ltration 12 .…”

Section: Introductionmentioning

confidence: 99%

A Pan-Cancer Analysis of the Oncogenic Role of YKT6 in Human Tumors

Zhang

Dapar

Chen

et al. 2022

Preprint

View full text Add to dashboard Cite

YKT6, as a Soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) protein with vesicle trafficking, plays an essential role in the development and progression of tumor. However, the gene of YKT6 has not been fully assessed in pan-cancer studies. We aim to investigate the gene of YKT6 across 33 different types of tumor by using the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) database, and other several kinds of bioinformatic tools. YKT6 is significantly up-regulated in most tumors, and we found that overexpression of YKT6 is positively associated with poor prognosis of overall survival (OS) and poor disease-free survival (DFS) prognosis in several tumors, such as Adrenocortical carcinoma (ACC), Bladder Urothelial Carcinoma (BLCA), Head and Neck squamous cell carcinoma (HNSC). We also detected distinct associations exist between YKT6 and tumor mutational burden (TMB) or microsatellite instability (MSI) with tumors. YKT6 expression was positively related to cancer-associated fibroblasts for TCGA tumors of COAD and LGG. Furthermore, we discovered a significantly positively correlation between YKT6 expression and endothelial cell in tumors of COAD, HNSC-HPV+, OV, READ and THCA. While a negative relationship was obtained between YKT6 expression and endothelial cell in KIRC. Moreover, “Syntaxin binding”, “SNARE complex”, “vesicle fusion” and “DNA replication” are involved in the influence of YKT6 on tumor pathogenesis. Our pan-cancer analysis offers a deep comprehending the gene of YKT6 in tumoeigenesis from viewpoint of clinical tumor samples.

show abstract

“…The expression levels of YKT6 and PNCK in HCC are also related to the Edmondson stage. The higher the stage, the higher the expression of YKT6 and PNCK, and the worse the prognosis of patients [ 24 , 25 ]. The trauma caused by surgery, the reduction of postoperative immunity, and the acceleration of hepatocyte regeneration after surgery lead to the growth of potential micrometastasis [ 26 ], which leads to the early recurrence and a poor prognosis of HCC.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Survival and Risk Factors in Patients with Hepatitis B-Related Hepatocellular Carcinoma: A Real-World Study

Zhu

Zhang

et al. 2022

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

A retrospective cohort study was conducted to collect 465 patients with hepatitis B-related hepatocellular carcinoma who had undergone radical hepatectomy from January 1, 2012, to August 31, 2018, at the First Affiliated Hospital of the University of Science and Technology of China. The clinical, pathological, and follow-up information was collected to compare the basic characteristics of death and nondeath after radical resection. Kaplan–Meier curves were used for survival analysis and male and female subgroup analysis. The multivariate Cox proportional-hazards regression model was used to analyze independent risk factors related to postoperative death. Of the 465 patients with radical resection of hepatitis B-related hepatocellular carcinoma, 132 died, and 1-, 3-, and 5-year cumulative survival rates after operation were 92.1%, 78%, and 64%, respectively. In the male and female subgroup, 115 and 17 patients died, respectively. The 1-, 3-, and 5-year cumulative survival rates were 92.6%, 77.0%, and 62.6%, respectively, in men, and 89.6%, 78.8%, and 70.2%, respectively, in women. Multivariate Cox proportional-hazards regression analysis showed that microvascular invasion (MVI), Edmondson III/IV, BCLC stage B, and total bilirubin (TB) > 20.5 μmol/L were independent risk factors in patients with hepatitis B-related hepatocellular carcinoma after radical hepatectomy.

show abstract

High expression of YKT6 associated with progression and poor prognosis of hepatocellular carcinoma

Cited by 15 publications

References 14 publications

High expression of serine and arginine-rich splicing factor 9 (SRSF9) is associated with hepatocellular carcinoma progression and a poor prognosis

High expression of serine and arginine-rich splicing factor 9 (SRSF9) is associated with hepatocellular carcinoma progression and a poor prognosis

A Pan-Cancer Analysis of the Oncogenic Role of YKT6 in Human Tumors

Long-Term Survival and Risk Factors in Patients with Hepatitis B-Related Hepatocellular Carcinoma: A Real-World Study

Contact Info

Product

Resources

About